We are live on ! Find out more
CLSD

Clearside Biomedical
CLSD

Delisted

CLSD was delisted on the 28th of November, 2025.

Back to rankings

46 hedge funds and large institutions have $9.23M invested in Clearside Biomedical in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

258% more call options, than puts

Call options by funds: $118K | Put options by funds: $33K

38% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 8

35% more capital invested

Capital invested by funds: $6.82M → $9.23M (+$2.41M)

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

2% more funds holding

Funds holding: 45 → 46 (+1)

0% more ownership

Funds ownership: 0.84% → 0.84% (+0%)

Holders
46
Holders Change
+1
Holders Change %
+2.22%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
11
Reduced
8
Closed
8
Calls
$118K
Puts
$33K
Net Calls
+$85K
Net Calls Change
+$80K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$115K
2
Renaissance Technologies
Renaissance Technologies
New York
+$106K
3
N
Natixis
France
+$45.2K
4
Millennium Management
Millennium Management
New York
+$32K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$29.6K

Top Sellers

Rank Fund Capital Flow
1
WIC
Water Island Capital
New York
-$71.8K
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$62.4K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$54.7K
4
S
SignatureFD
Georgia
-$47.1K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$42.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.55M +$8.97K +629 +0.4%
CG
2
Carmignac Gestion
France
$2.5M – – –
BlackRock
3
BlackRock
New York
$889K -$3.31K -232 -0.5%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$574K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$450K +$106K +7,427 +41%
Morgan Stanley
6
Morgan Stanley
New York
$338K +$115K +8,073 +72%
State Street
7
State Street
Massachusetts
$226K – – –
BCM
8
Bridgeway Capital Management
Texas
$205K – – –
First Manhattan
9
First Manhattan
New York
$205K – – –
JJ
10
Johnson & Johnson
New Jersey
$198K – – –
BWM
11
Brown Wealth Management
Illinois
$129K – – –
NFC
12
Northeast Financial Consultants
Connecticut
$109K +$9.51K +667 +12%
Northern Trust
13
Northern Trust
Illinois
$107K -$2.87K -201 -3%
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$105K +$29.6K +2,073 +53%
SF
15
Synovus Financial
Georgia
$62.1K -$4.75K -333 -9%
CAPTRUST Financial Advisors
16
CAPTRUST Financial Advisors
North Carolina
$58.5K – – –
N
17
Natixis
France
$55.6K +$45.2K +3,167 New
Citadel Advisors
18
Citadel Advisors
Florida
$53.6K +$24.8K +1,739 +132%
BCV
19
Banque Cantonale Vaudoise
Switzerland
$47K – – –
Stifel Financial
20
Stifel Financial
Missouri
$39.8K -$18.5K -1,300 -36%
Millennium Management
21
Millennium Management
New York
$39.4K +$32K +2,243 New
Bank of New York Mellon
22
Bank of New York Mellon
New York
$34.5K – – –
NDSI
23
Newman Dignan & Sheerar Inc
Rhode Island
$32.8K +$26.6K +1,868 New
CWM
24
Curi Wealth Management
North Carolina
$29.3K – – –
Charles Schwab
25
Charles Schwab
California
$23.7K – – –
1
2 3

CLSD Hedge Fund Activity: Q4 2023 in Review

46 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2023, worth a combined $9.23M — up 35% from $6.82M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new CLSD positions and 8 closed out — a net gain of 1 holder — while 11 added to existing stakes and 8 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $115K. The largest seller was Water Island Capital, exiting entirely with an estimated $71.8K sold.

  • 46 institutional investors held Clearside Biomedical (CLSD) as of Q4 2023, up from 45 in Q3 2023.
  • Funds reported $9.23M of Clearside Biomedical stock for Q4 2023, up 35% quarter-over-quarter.
  • 9 funds opened new Clearside Biomedical positions in Q4 2023 and 8 closed out, a net change of +1 holder.
  • The largest Clearside Biomedical buyer in Q4 2023 was Morgan Stanley, an estimated $115K added.
  • The largest Clearside Biomedical seller in Q4 2023 was Water Island Capital, an estimated $71.8K sold.

Based on aggregated 13F filings for Q4 2023.